ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för Abemaciclib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

38 träffar

Bibliografisk träff 2024-04-24

Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor.

Xu Z, Liu Y, Song B, Ren B, Xu X, Lin R, Zhu X, Chen C, Yang S, Zhu Y, Jiang W, Li W, Xia Y, Hu L, Chen S, Chan CC, Li J, Zhang X, Yang L, Tian X, Ding CZ.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2024.129769

Bibliografisk träff 2023-12-20

Discovery of pyrazolo[3,4-d]pyrimidines as novel mitogen-activated protein kinase kinase 3 (MKK3) inhibitors.

Takarada JE, Cunha MR, Almeida VM, Vasconcelos SNS, Santiago AS, Godoi PH, Salmazo A, Ramos PZ, Fala AM, de Souza LR, Da Silva IEP, Bengtson MH, Massirer KB, Couñago RM.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2023.117561

Bibliografisk träff 2023-11-24

Novel indolyl 1,2,4-triazole derivatives as potential anti-proliferative agents: in silico studies, synthesis, and biological evaluation.

Ghobish SA, Mohamed KO, Farag N, Farag DB.

RSC Med Chem · research-article; journal article · DOI 10.1039/d3md00524k

Bibliografisk träff 2023-07-23

The mystery of titan hunter: Rationalized striking of the MAPK pathway via Newly synthesized 6-Indolylpyridone-3-Carbonitrile derivatives.

Saleh MM, El-Moselhy T, El-Bastawissy E, Ibrahim MAA, Sayed SRM, Hegazy MF, Efferth T, Jaragh-Alhadad LA, Sidhom PA.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2023.115675

Bibliografisk träff 2023-07-19

A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.

Sutherland JJ, Yonchev D, Fekete A, Urban L.

Nat Commun · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41467-023-40064-9

Bibliografisk träff 2023-03-06

Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases.

Lindberg MF, Deau E, Arfwedson J, George N, George P, Alfonso P, Corrionero A, Meijer L.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.2c02068

Bibliografisk träff 2023-03-06

Recent updates on 1,2,3-triazole-containing hybrids with in vivo therapeutic potential against cancers: A mini-review.

Zhao S, Liu J, Lv Z, Zhang G, Xu Z.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.115254

Bibliografisk träff 2022-11-09

Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer.

Chen W, Ji M, Cheng H, Zheng M, Xia F, Min W, Yang H, Wang X, Wang L, Cao L, Yuan K, Yang P.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.2c00947

Bibliografisk träff 2022-04-29

From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.

Shi Z, Tian L, Qiang T, Li J, Xing Y, Ren X, Liu C, Liang C.

J Med Chem · research support, non-u.s. gov't; systematic review; journal article · DOI 10.1021/acs.jmedchem.1c02064

Bibliografisk träff 2022-04-21

Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.

Chen X, Shu C, Li W, Hou Q, Luo G, Yang K, Wu X.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.2c00063

Bibliografisk träff 2021-11-29

Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma.

Yuan K, Kuang W, Chen W, Ji M, Min W, Zhu Y, Hou Y, Wang X, Li J, Wang L, Yang P.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2021.114024

Bibliografisk träff 2021-06-03

Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.

Pillaiyar T, Laufer S.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.1c00335

Bibliografisk träff 2021-05-10

Kinase Inhibitors as Underexplored Antiviral Agents.

García-Cárceles J, Caballero E, Gil C, Martínez A.

J Med Chem · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1021/acs.jmedchem.1c00302

Bibliografisk träff 2021-03-02

Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions.

Liao M, Zhang J, Wang G, Wang L, Liu J, Ouyang L, Liu B.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.0c01180

Bibliografisk träff 2021-02-11

Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.

Lin T, Li J, Liu L, Li Y, Jiang H, Chen K, Xu P, Luo C, Zhou B.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2021.113281

Bibliografisk träff 2020-12-13

Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.

Shi X, Quan Y, Wang Y, Wang Y, Li Y.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2020.127725

Bibliografisk träff 2020-10-08

Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.

Bass AKA, El-Zoghbi MS, Nageeb EM, Mohamed MFA, Badr M, Abuo-Rahma GEA.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2020.112904

Bibliografisk träff 2020-03-16

Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.

Shi C, Wang Q, Liao X, Ge H, Huo G, Zhang L, Chen N, Zhai X, Hong Y, Wang L, Wang Z, Shi W, Mao Y, Yu J, Ke Y, Xia G.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2020.112239

Bibliografisk träff 2020-03-12

Discovery and SARs of 5-Chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity.

Wang Y, Chen X, Yan Y, Zhu X, Liu M, Liu X.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.9b02121

Bibliografisk träff 2019-08-29

Are all cyclin-dependent kinases 4/6 inhibitors created equal?

Marra A, Curigliano G.

NPJ Breast Cancer · review-article; review; journal article · DOI 10.1038/s41523-019-0121-y

Bibliografisk träff 2019-07-28

Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis.

Huang Z, Zhao B, Qin Z, Li Y, Wang T, Zhou W, Zheng J, Yang S, Shi Y, Fan Y, Xiang R.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.07.044

Bibliografisk träff 2019-06-26

Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.

Bronner SM, Merrick KA, Murray J, Salphati L, Moffat JG, Pang J, Sneeringer CJ, Dompe N, Cyr P, Purkey H, Boenig GL, Li J, Kolesnikov A, Larouche-Gauthier R, Lai KW, Shen X, Aubert-Nicol S, Chen YC, Cheong J, Crawford JJ, Hafner M, Haghshenas P, Jakalian A, Leclerc JP, Lim NK, O'Brien T, Plise EG, Shalan H, Sturino C, Wai J, Xiao Y, Yin J, Zhao L, Gould S, Olivero A, Heffron TP.

Bioorg Med Chem Lett · research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1016/j.bmcl.2019.06.021

Bibliografisk träff 2019-06-04

Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.

Shi C, Wang Q, Liao X, Ge H, Huo G, Zhang L, Chen N, Zhai X, Hong Y, Wang L, Han Y, Xiao W, Wang Z, Shi W, Mao Y, Yu J, Xia G, Liu Y.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.06.005

Bibliografisk träff 2019-04-04

Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.

Poratti M, Marzaro G.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2019.03.064

Bibliografisk träff 2019-01-03

Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.

Cheng W, Yang Z, Wang S, Li Y, Wei H, Tian X, Kan Q.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2019.01.003

Bibliografisk träff 2018-10-05

How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?

Jorda R, Hendrychová D, Voller J, Řezníčková E, Gucký T, Kryštof V.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.8b00049

Bibliografisk träff 2018-02-12

Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy.

Zha C, Deng W, Fu Y, Tang S, Lan X, Ye Y, Su Y, Jiang L, Chen Y, Huang Y, Ding J, Geng M, Huang M, Wan H.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2018.02.022

Bibliografisk träff 2018-01-31

Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.

Wang Y, Liu WJ, Yin L, Li H, Chen ZH, Zhu DX, Song XQ, Cheng ZZ, Song P, Wang Z, Li ZG.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2017.12.068

Bibliografisk träff 2017-12-06

A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.

Yin L, Li H, Liu W, Yao Z, Cheng Z, Zhang H, Zou H.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2017.12.003

Bibliografisk träff 2017-12-01

The target landscape of clinical kinase drugs.

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B.

Science · research support, non-u.s. gov't; research-article; journal article · DOI 10.1126/science.aan4368

Gå till forskningen.

Publikationer i urvalet

Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor.

Discovery of pyrazolo[3,4-d]pyrimidines as novel mitogen-activated protein kinase kinase 3 (MKK3) inhibitors.

Novel indolyl 1,2,4-triazole derivatives as potential anti-proliferative agents: <i>in silico</i> studies, synthesis, and biological evaluation.

The mystery of titan hunter: Rationalized striking of the MAPK pathway via Newly synthesized 6-Indolylpyridone-3-Carbonitrile derivatives.

A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.

Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases.

Recent updates on 1,2,3-triazole-containing hybrids with in vivo therapeutic potential against cancers: A mini-review.

Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer.

From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.

Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.

Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma.

Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.

Kinase Inhibitors as Underexplored Antiviral Agents.

Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions.

Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.

Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.

Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.

Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.

Discovery and SARs of 5-Chloro-<i>N</i><sup>4</sup>-phenyl-<i>N</i><sup>2</sup>-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity.

Are all cyclin-dependent kinases 4/6 inhibitors created equal?

Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis.

Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.

Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.

Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.

Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.

How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?

Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy.

Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.

A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.

The target landscape of clinical kinase drugs.